Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for Amyotrophic Lateral Sclerosis (ALS)

Relyvrio (formerly AMX0035) is an oral fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO). PB is a prescription drug used to treat urea cycle disorders and TURSO (also known as tauroursodeoxycholic acid [TUDCA]) is a widely available non-prescription supplement. Relyvrio is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults…

read more

Etranacogene Dezaparvovec for Hemophilia B

Etranacogene dezaparvovec (formerly AMT-061) is an investigational recombinant gene transfer therapy product designed to help patients with hemophilia B produce sufficient plasma levels of endogenous coagulation factor IX (FIX). The main therapeutic goal is long-term expression of FIX at levels steady enough to eliminate the need for routine prophylactic replacement therapy w…

read more